An expensive new haemophilia gene therapy hits the US
The approval is good for CSL, and better for Uniqure.
Go or no go? Apellis eyes an FDA outcome
Immunogen and Uniqure are also set for Pdufa conclusions.
Zynteglo gets the nod, and the hard work begins
Bluebird’s gene therapy is to be launched in the US priced $2.8m per patient, but can the company tread the cautious path to profitability?